Filing Flows › Prime Medicine (PRME) › Q3 2025 › vs Q3 2024
Prime Medicine (PRME) Q3 2025 vs Q3 2024 (year over year)
Prime Medicine's revenue rose $1.0M (+486%) from $209K in Q3 2024 to $1.2M in Q3 2025.
Prime Medicine, Q3 2025: revenue $1.2M (+486% year over year), net loss $50.6M, operating cash flow −$35.0M. The chart draws each line against Q3 2024, the increases inside each band.
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2M | $209K | $1.0M | +486% |
| Other income, net | $3.4M | $1.7M | $1.7M | +98% |
| Net loss | $50.6M | $52.5M | −$1.9M | -4% |
| Costs & expenses | $55.2M | $54.4M | $757K | +1% |
| Operating costs | $55.2M | $54.4M | $757K | +1% |
| Research & development | $44.0M | $40.3M | $3.6M | +9% |
| General & admin | $11.2M | $14.1M | −$2.9M | -21% |
| Operating cash sources | $50.6M | $52.5M | −$1.9M | -4% |
| Depreciation & amortization | $1.9M | $1.6M | $323K | +21% |
| Share-based compensation | $12.7M | $6.8M | $5.9M | +87% |
| Working capital & other | $915K | $18.2M | −$17.3M | -95% |
| Cash used in operations | $35.0M | $25.9M | $9.1M | +35% |
| Net loss absorbed | $50.6M | $52.5M | −$1.9M | -4% |
Questions
How much did Prime Medicine's revenue grow year over year in Q3 2025?
Prime Medicine's revenue rose $1.0M (+486%) from $209K in Q3 2024 to $1.2M in Q3 2025.